ReviewOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2026
Therapeutic potential of fish collagen hydrolysates in osteoporosis prevention: a narrative review based on cellular, molecular, and clinical evidence.
Review in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is a prevalent bone disorder diagnosed by diminished bone density and deterioration of skeletal microarchitecture. Adverse side effects caused by the prolonged use of anti-osteoporotic medications have prompted researchers to find safe and natural therapeutic compounds to manage osteoporosis. Among natural compounds, fish collagen hydrolysates (FCHs) derived from fish processing wastes offer a safe, inexpensive, and environment-friendly alternative to mammalian collagen. This review critically evaluates the preclinical and clinical evidence for the therapeutic effectiveness of FCHs on bone cell biology, highlighting their potential in osteoporosis prevention. The review also highlights high bioavailability, biocompatibility, and the potential of fish collagen peptides to influence bone metabolism. Evidence of increased bone mineral density and improved bone microarchitecture has also been discussed in vivo, along with key regulatory markers of osteoblasts and osteoclasts function, including alkaline phosphatase (ALP), osteocalcin (OCN), osteopontin (OPN), runt-related transcription factor-2 (Runx-2), bone morphogenetic protein (BMP-2), receptor activator of nuclear factor κ B ligand (RANKL), tartrate-resistant acid phosphatase (TRAP), and cathepsin K. Although early clinical trials suggest beneficial effects on bone turnover and bone mineral density, robust, large-scale randomized studies are still needed to confirm these findings. FCHs thus present a promising but still developing therapeutic avenue in the prevention and management of osteoporosis.
Indexed as
Identifiers
41028243What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.